Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of IMC002 versus investigator's choice therapy in CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines
CTR20252202Phase 3Active
- Sponsor
- EyeBio
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IMC-002 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by EyeBio. Started Aug 2025; status: active.
02
Drugs
IMC-002
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20252202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252202.